GlassScriptPhysician profile
Misty Colley
NPI 1699483495
$781.61
in general payments reported to CMS, 2019-2025
17 companies · $680 in 2025
The $680 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $38.92 · 2024: $62.63 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $98.52 | 2025 | Jornay Pm |
| Abbvie INC. | $97.78 | 2025 | |
| Vanda Pharmaceuticals INC. | $87.47 | 2024-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $78.38 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $65.74 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $53.04 | 2025 | Austedo Xr |
| Dexcom, INC. | $49.98 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $48.26 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $38.59 | 2025 | Airsupra, Fasenra |
| Indivior INC. | $34.34 | 2024 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.67 | 2025 | Caplyta |
| Globus Medical, INC. | $21.62 | 2025 | Senza |
| Idorsia Pharmaceuticals US INC | $20.62 | 2023 | Quviviq |
| Abbott Laboratories | $15.46 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $15.13 | 2025 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $14.30 | 2025 | Nexletol |
| Amgen INC. | $13.71 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Colley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.